Fate Therapeutics (FATE) Restructuring Costs (2023)

Fate Therapeutics (FATE) posted Restructuring Costs of $2.0 million for Q1 2023.

Fate Therapeutics (FATE) Restructuring Costs (2023) Analysis & Trends

Fate Therapeutics' Restructuring Costs history runs 1 years deep, the most recent figure standing at $2.0 million for Q1 2023.

Quarterly Restructuring Costs changed N/A year-over-year to $2.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (changed N/A YoY) and the FY2023 annual result came in at $2.0 million, changed N/A from the prior year.
Restructuring Costs was $2.0 million for Q1 2023 at Fate Therapeutics.
Across five years, Restructuring Costs topped out at $2.0 million in Q1 2023 and bottomed at $2.0 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Fate Therapeutics	288.82 Mn	288.82 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2023	2.00 Mn